Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients

A. Rehulkova, J. Chudacek, A. Prokopova, M. Vidlarova, J. Stranska, J. Drabek, J. Potockova, R. Trojanec, J. Vrbkova, J. Skarda, T. Bohanes, M. Szkorupa, B. Tolmaci, J. Klein, J. Srovnal, M. Hajduch

. 2023 ; 12 (5) : 1034-1050. [pub] 20230417

Status neindexováno Jazyk angličtina Země Čína

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23009664

BACKGROUND: Surgical treatment of early-stage non-small cell lung cancer (NSCLC) yields highest expectations for recovery. However, the frequency of further disease progression remains high since micro-metastatic disease may be undetected by conventional diagnostic methods. We test the presence and prognostic impact of circulating tumor cells (CTCs) in peripheral blood (PB), tumor-draining pulmonary blood (TDB) and bone marrow (BM) samples from NSCLC patients. METHODS: The presence of circulating/disseminated tumor cells (CTCs/DTCs) was detected by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis in PB, TDB and BM samples before surgery in 119 stage IA-IIIA NSCLC patients (Clinical Trial NS10285). RESULTS: NSCLC patients with the presence of carcinoembryonic antigen (CEA) mRNA-positive CTCs/DTCs in TDB and BM had significantly shorter cancer-specific survival (CSS) (P<0.013, resp. P<0.038). Patients with the presence of epithelial cellular adhesion molecule (EpCAM) mRNA-positive CTCs in TDB samples had significantly shorter CSS and disease-free survival (DFS) (P<0.031, resp. P<0.045). A multivariate analysis identified the presence of CEA mRNA-positive CTCs in the PB as an independent negative prognostic factor for DFS (P<0.005). No significant correlation of CTCs/DTCs presence and other prognostic factors was found. CONCLUSIONS: In NSCLC patients undergoing radical surgery, the presence of CEA and EpCAM mRNA-positive CTCs/DTCs is associated with poorer survival.

000      
00000naa a2200000 a 4500
001      
bmc23009664
003      
CZ-PrNML
005      
20240206140117.0
007      
ta
008      
230707s2023 cc f 000 0|eng||
009      
AR
024    7_
$a 10.21037/tlcr-22-801 $2 doi
035    __
$a (PubMed)37323172
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a cc
100    1_
$a Rehulkova, Alona $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital in Olomouc, Olomouc, Czech Republic $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic $u Department of Surgery, Tomas Bata Regional Hospital, Zlin, Czech Republic
245    10
$a Clinical and prognostic significance of detecting CEA, EGFR, LunX, c-met and EpCAM mRNA-positive cells in the peripheral blood, tumor-draining blood and bone marrow of non-small cell lung cancer patients / $c A. Rehulkova, J. Chudacek, A. Prokopova, M. Vidlarova, J. Stranska, J. Drabek, J. Potockova, R. Trojanec, J. Vrbkova, J. Skarda, T. Bohanes, M. Szkorupa, B. Tolmaci, J. Klein, J. Srovnal, M. Hajduch
520    9_
$a BACKGROUND: Surgical treatment of early-stage non-small cell lung cancer (NSCLC) yields highest expectations for recovery. However, the frequency of further disease progression remains high since micro-metastatic disease may be undetected by conventional diagnostic methods. We test the presence and prognostic impact of circulating tumor cells (CTCs) in peripheral blood (PB), tumor-draining pulmonary blood (TDB) and bone marrow (BM) samples from NSCLC patients. METHODS: The presence of circulating/disseminated tumor cells (CTCs/DTCs) was detected by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) analysis in PB, TDB and BM samples before surgery in 119 stage IA-IIIA NSCLC patients (Clinical Trial NS10285). RESULTS: NSCLC patients with the presence of carcinoembryonic antigen (CEA) mRNA-positive CTCs/DTCs in TDB and BM had significantly shorter cancer-specific survival (CSS) (P<0.013, resp. P<0.038). Patients with the presence of epithelial cellular adhesion molecule (EpCAM) mRNA-positive CTCs in TDB samples had significantly shorter CSS and disease-free survival (DFS) (P<0.031, resp. P<0.045). A multivariate analysis identified the presence of CEA mRNA-positive CTCs in the PB as an independent negative prognostic factor for DFS (P<0.005). No significant correlation of CTCs/DTCs presence and other prognostic factors was found. CONCLUSIONS: In NSCLC patients undergoing radical surgery, the presence of CEA and EpCAM mRNA-positive CTCs/DTCs is associated with poorer survival.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chudacek, Josef $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic
700    1_
$a Prokopova, Andrea $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Vidlarova, Monika $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Stranska, Jana $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital in Olomouc, Olomouc, Czech Republic
700    1_
$a Drabek, Jiri $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital in Olomouc, Olomouc, Czech Republic
700    1_
$a Potockova, Jana $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Trojanec, Radek $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic
700    1_
$a Vrbková, Jana, $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic $d 1971- $7 xx0105359
700    1_
$a Skarda, Josef $u Institute of Molecular and Clinical Pathology and Medical Genetics, Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
700    1_
$a Bohanes, Tomas $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic $u Department of Thoracic Surgery, Clinic Floridsdorf, Vienna, Austria
700    1_
$a Szkorupa, Marek $u Department of Surgery, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic
700    1_
$a Tolmaci, Benjamin $u Department of Surgery, Tomas Bata Regional Hospital, Zlin, Czech Republic
700    1_
$a Klein, Jiri $u Department of Surgery, Tomas Bata Regional Hospital, Zlin, Czech Republic $u Faculty of Healthcare, Alexander Dubcek University of Trencin, Trencin, Slovakia
700    1_
$a Srovnal, Josef $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital in Olomouc, Olomouc, Czech Republic $u Cancer Research Czech Republic, Olomouc, Czech Republic
700    1_
$a Hajduch, Marian $u Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Czech Advanced Technology and Research Institute, Palacky University in Olomouc, Olomouc, Czech Republic $u Laboratory of Experimental Medicine, University Hospital in Olomouc, Olomouc, Czech Republic $u Cancer Research Czech Republic, Olomouc, Czech Republic
773    0_
$w MED00186389 $t Translational lung cancer research $x 2218-6751 $g Roč. 12, č. 5 (2023), s. 1034-1050
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37323172 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230707 $b ABA008
991    __
$a 20240206140114 $b ABA008
999    __
$a ok $b bmc $g 1958458 $s 1195928
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2023 $b 12 $c 5 $d 1034-1050 $e 20230417 $i 2218-6751 $m Translational lung cancer research $n Transl Lung Cancer Res $x MED00186389
LZP    __
$a Pubmed-20230707

Najít záznam

Citační ukazatele

Možnosti archivace